Rebecca J. Jaslow, MD

4.86 out of 5 (72 ratings, 14 reviews)
Ratings and Reviews

Departments

Cooper University Health Care Titles

  • Co-Director, William G. Rohrer Cancer Genetics Program
  • Hematologist/Medical Oncologist

Board Certifications

  • American Board of Internal Medicine (Medical Oncology)

Professional Type

Cooper University Physician

NPI

1992774996

Office Locations

Camden, Voorhees, Moorestown
MD Anderson Cancer Center at Cooper - Voorhees

900 Centennial Boulevard
Building 1
Suite F
Voorhees , NJ 08043
Phone: 855.MDA.COOPER (855.632.2667)
Fax: 856.325.6645
Maps & Directions

Cooper University Health Care Moorestown Campus

400 NJ-38
Moorestown Mall
Moorestown , NJ 08057
Phone: 855.632.2667
Maps & Directions

Education & Training

Medical SchoolMount Sinai School of Medicine, New York, NY
InternshipInternal Medicine - Mount Sinai Hospital, New York, NY
ResidencyInternal Medicine - Mount Sinai Hospital, New York, NY
FellowshipHematology and Oncology - New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY

Memberships

  • American Society of Clinical Oncology

Publications

Wang C, Mu Z, Ye Z, Zhang Z, Abu-Khalaf MM, Silver DP, Palazzo JP, Jagannathan G, Fellin FM, Bhattacharya S, Jaslow RJ, Tsangaris TN, Berger A, Neupane M, Cescon TP, Lopez A, Yao K, Chong W, Lu B, Myers RE, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020 Jun;181(3):679-689. doi: 10.1007/s10549-020-05662-x. Epub 2020 May 4. PMID: 32367460; PMCID: PMC7299127.

Laufer T, Lerner B, Petrich A, Quinn AM, Ernst L, Roop A, Knoblauch J, Leasure NC, Jaslow RJ, Hegarty S, Leader A, Barsevick A. Evaluation of a Technology-Based Survivor Care Plan for Breast Cancer Survivors: Pre-Post Pilot Study. JMIR Cancer. 2019 Dec 20;5(2):e12090. doi: 10.2196/12090. PMID: 31859683; PMCID: PMC6942181.

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102.

Ye Z, Wang C, Wan S, Mu Z, Zhang Z, Abu-Khalaf MM, Fellin FM, Silver DP, Neupane M, Jaslow RJ, Bhattacharya S, Tsangaris TN, Chervoneva I, Berger A, Austin L, Palazzo JP, Myers RE, Pancholy N, Toorkey D, Yao K, Krall M, Li X, Chen X, Fu X, Xing J, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. Eur J Cancer. 2019 Jan;106:133-143. doi: 10.1016/j.ejca.2018.10.012. Epub 2018 Dec 4. PMID: 30528798; PMCID: PMC6347110.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. PMID: 29146401.

Ratings and Reviews

Ratings and reviews come from patient responses to health care provider-related questions on the Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG-CAHPS) Patient Experience Survey that Cooper sends to patients after outpatient office visits.  Learn more about our survey and how ratings are calculated >>

Overall Rating

4.86 out of 5 (72 ratings, 14 reviews)
Apr 12, 2025
Everyone was courteous and friendly.
Mar 12, 2025
Hi. Dr. Jaslow was awesome. This was my first appointment with her. I was very impressed. She's very thorough, very knowledgeable, gave me a lot of information, and I appreciate it very much. Thank you.
Mar 12, 2025
Dr. Jaslow is very, very professional, very, very informative, and very, very caring and nurturing. Thank you.
Mar 12, 2025
Excellent and caring staff. Everyone works together and gets results and appointments fast
Feb 12, 2025
I like the doctor She is very busy
Feb 12, 2025
Dr Rebecca Jaslow has always been the most knowledgeable, professional and friendly at each visit I've had with her. I like her very much and am confident in her treatment.
Feb 12, 2025
Hearing "you have cancer" is life changing. Scary. Everyone at MD Anderson made scary go away. I felt like I was in the very best of care. We made a plan and attacked cancer head on from day one and haven't looked back!
Feb 12, 2025
Follow-up after my dexascan was spotty. I left 2 messages and was not called back. Until I called my nurse navigator.
Feb 12, 2025
I could not be happier with my entire Cooper team.
Feb 12, 2025
Medical assistant was exceptional